Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a buy rating to a strong-buy rating in a report published on Saturday.

Several other equities analysts have also recently commented on the stock. Bank of America cut shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a report on Wednesday, October 15th. Zacks Research raised Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Finally, UBS Group downgraded Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Fresenius Medical Care AG & Co. KGaA presently has a consensus rating of “Hold” and a consensus price target of $27.80.

Fresenius Medical Care AG & Co. KGaA Price Performance

NYSE FMS opened at $27.17 on Friday. The company has a 50 day simple moving average of $25.92 and a 200-day simple moving average of $26.48. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.44 and a quick ratio of 1.08. The firm has a market capitalization of $15.94 billion, a price-to-earnings ratio of 22.27, a price-to-earnings-growth ratio of 0.65 and a beta of 0.92. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $18.94 and a 52-week high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.02. The firm had revenue of $5.54 billion for the quarter, compared to analyst estimates of $5 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. Equities research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of large investors have recently added to or reduced their stakes in the stock. Crossmark Global Holdings Inc. boosted its position in Fresenius Medical Care AG & Co. KGaA by 0.9% during the first quarter. Crossmark Global Holdings Inc. now owns 64,871 shares of the company’s stock worth $1,615,000 after purchasing an additional 584 shares during the period. GAMMA Investing LLC lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 5.9% in the third quarter. GAMMA Investing LLC now owns 10,437 shares of the company’s stock worth $275,000 after buying an additional 585 shares during the last quarter. Yousif Capital Management LLC raised its holdings in Fresenius Medical Care AG & Co. KGaA by 6.8% in the 2nd quarter. Yousif Capital Management LLC now owns 9,804 shares of the company’s stock worth $280,000 after acquiring an additional 625 shares during the period. Callan Capital LLC raised its holdings in Fresenius Medical Care AG & Co. KGaA by 6.6% in the 1st quarter. Callan Capital LLC now owns 13,974 shares of the company’s stock worth $348,000 after acquiring an additional 870 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in Fresenius Medical Care AG & Co. KGaA by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock worth $146,000 after acquiring an additional 896 shares during the period. Institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.